Thus, PDX models may provide a method for precise preclinical evaluation for novel CAR-T immunotherapies.46 There was a report that GPC3-positive PDX mouse model for HCC was well-established and characterized, and showed significantly suppressed tumor growth by treatment of GPC3-CAR-T cells.47 Therefore, we further performed CAT-T treatment by using the PDX model in vivo to test the efficacies and safety of CD105 CAR-T cell therapy. The gene discussed is GPC3; the disease is hepatocellular carcinoma.